Literature DB >> 17415646

Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients.

Jan-Erik Johansson1, Tor Ekman.   

Abstract

Graft-versus-host disease (GVHD) is the primary complication of allogeneic, hemopoietic, stem cell transplantation (HSCT). Murine models suggest that gut toxicity, induced by the intensive chemotherapy preceding hematopoietic stem cell infusion, aggravates systemic GVHD. In HSCT patients gut toxicity correlates with chemotherapy intensity. The present study investigates acute GVHD severity and intestinal toxicity in patients undergoing allogeneic HSCT. In 38 patients intestinal permeability was assessed before and after chemotherapy (on days -1, +4, +7 and +14 as related to the stem cell infusion). Cumulative acute GVHD (days 0-100) and clinical intestinal toxicity (days 0-14) were evaluated in parallel. Patients with mild, acute GVHD (grades 0-I) had better-preserved intestinal barrier function (P=0.04) and less pronounced cumulative clinical intestinal toxicity (P=0.02) compared with patients with more severe acute GVHD (grades II-IV). Gut toxicity predicts acute GVHD severity. Therefore, gut protective strategies may diminish GVHD severity in allogeneic HSCT patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415646     DOI: 10.1007/s10620-006-9404-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings.

Authors:  J E Johansson; T Ekman
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

2.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

3.  The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.

Authors:  J E Johansson; M Brune; T Ekman
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

4.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice.

Authors:  C Q Xun; J S Thompson; C D Jennings; S A Brown; M B Widmer
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

5.  Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  A Panoskaltsis-Mortari; D L Lacey; D A Vallera; B R Blazar
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

Review 6.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

7.  Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration.

Authors:  S Lehnert; W B Rybka
Journal:  Bone Marrow Transplant       Date:  1994-04       Impact factor: 5.483

8.  Amplification of the graft-versus-host reaction by partial body irradiation.

Authors:  S Lehnert; W B Rybka; T A Seemayer
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

9.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

10.  Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F).

Authors:  E Holler; H J Kolb; J Mittermüller; M Kaul; G Ledderose; T Duell; B Seeber; M Schleuning; R Hintermeier-Knabe; B Ertl
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more
  19 in total

1.  Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Authors:  Parvathi Ranganathan; Apollinaire Ngankeu; Nina C Zitzer; PierPaolo Leoncini; Xueyan Yu; Lucia Casadei; Kishore Challagundla; Dawn K Reichenbach; Sabrina Garman; Amy S Ruppert; Stefano Volinia; Jessica Hofstetter; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Muller Fabbri; Ramiro Garzon
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

Review 2.  The intestinal epithelial barrier: a therapeutic target?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

3.  Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.

Authors:  Tomoaki Ueda; Tomoyasu Jo; Kazuya Okada; Yasuyuki Arai; Takayuki Sato; Takeshi Maeda; Tatsuhito Onishi; Yasunori Ueda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

4.  Early post-transplant contrast-enhanced abdominopelvic CT scan predicts the risk of subsequent acute GvHD.

Authors:  A Rashidi; M F Lin; A F Cashen
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

Review 5.  Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.

Authors:  S C Nalle; J R Turner
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

Review 6.  Intestinal permeability defects: is it time to treat?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-12       Impact factor: 11.382

7.  Critical role for IL-1β in DNA damage-induced mucositis.

Authors:  Naama Kanarek; Sergei I Grivennikov; Michael Leshets; Audrey Lasry; Irit Alkalay; Elad Horwitz; Yoav D Shaul; Matthew Stachler; Elena Voronov; Ron N Apte; Michele Pagano; Eli Pikarsky; Michael Karin; Sankar Ghosh; Yinon Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

8.  Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.

Authors:  Sam C Nalle; H Aimee Kwak; Karen L Edelblum; Nora E Joseph; Gurminder Singh; Galina F Khramtsova; Eric D Mortenson; Peter A Savage; Jerrold R Turner
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

9.  The role of bacteria and pattern recognition receptors in GVHD.

Authors:  E Holler; K Landfried; J Meier; M Hausmann; G Rogler
Journal:  Int J Inflam       Date:  2010-10-31

Review 10.  Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease.

Authors:  Eileen Haring; Robert Zeiser; Petya Apostolova
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.